Iron Homeostasis and Pulmonary Hypertension

Circulation Research

116, 1680-1690

DOI: 10.1161/circresaha.116.305265

Citation Report

#	Article	IF	Citations
1	Iron, oxygen, and the pulmonary circulation. Journal of Applied Physiology, 2015, 119, 1421-1431.	1.2	22
2	Is Correction of Iron Deficiency a New Addition to the Treatment of the Heart Failure?. International Journal of Molecular Sciences, 2015, 16, 14056-14074.	1.8	30
4	microRNA and Pulmonary Hypertension. Advances in Experimental Medicine and Biology, 2015, 888, 237-252.	0.8	62
5	The zinc transporter ZIP12 regulates the pulmonary vascular response to chronic hypoxia. Nature, 2015, 524, 356-360.	13.7	113
6	Pulmonary Arterial Hypertension Is Associated with Oxidative Stressâ€“induced Genome Instability. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 129-130.	2.5	18
7	The Iron Paradigm of Pulmonary Arterial Hypertension. Circulation Research, 2015, 116, 1636-1638.	2.0	6
8	Letter by Mosley Regarding Article, â€œIron Homeostasis and Pulmonary Hypertension: Iron Deficiency Leads to Pulmonary Vascular Remodeling in the Ratâ€•. Circulation Research, 2015, 117, e56-7.	2.0	2
9	Clinical iron deficiency disturbs normal human responses to hypoxia. Journal of Clinical Investigation, 2016, 126, 2139-2150.	3.9	82
10	Relationship of Iron Deficiency and Serum Ferritin Levels with Pulmonary Hypertension: The Jackson Heart Study. PLoS ONE, 2016, 11, e0167987.	1.1	6
11	Molecular Mechanisms of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 2016, 17, 761.	1.8	114
12	Integration of Complex Data Sources to Provide Biologic Insight into Pulmonary Vascular Disease (2015 Grover Conference Series). Pulmonary Circulation, 2016, 6, 251-260.	0.8	11
13	Circulation Research â€œIn This Issueâ€•Anthology. Circulation Research, 2016, 119, .	2.0	0
14	Iron is associated with the development of hypoxia-induced pulmonary vascular remodeling in mice. Heart and Vessels, 2016, 31, 2074-2079.	0.5	7
15	Iron Metabolism and Vascular Remodeling: Novel Insights Provided by Transferrin-1 Receptor Depletion in Mice With Pulmonary Hypertension. American Journal of Hypertension, 2016, 29, 676-678.	1.0	1
16	Transferrin Receptor 1 in Chronic Hypoxia-Induced Pulmonary Vascular Remodeling. American Journal of Hypertension, 2016, 29, 713-718.	1.0	17
17	Iron Deficiency in COPD Associates with Increased Pulmonary Artery Pressure Estimated by Echocardiography. Heart Lung and Circulation, 2017, 26, 101-104.	0.2	23
18	The Relationship Between Iron Deficiency Anemia and Sensorineural Hearing Loss in the Pediatric and Adolescent Population. American Journal of Audiology, 2017, 26, 155-162.	0.5	24
19	InÂvivo biocompatibility and hemocompatibility of a polytetrafluoroethylene small diameter vascular graft modified with sulfonated silk fibroin. American Journal of Surgery, 2017, 213, 87-93.	0.9	28

#	Article	IF	Citations
20	Health Disparities in Patients with Pulmonary Arterial Hypertension: A Blueprint for Action. An Official American Thoracic Society Statement. American Journal of Respiratory and Critical Care Medicine, 2017, 196, e32-e47.	2.5	36
21	Lower systolic blood pressure at age 7 y in low-birth-weight children who received iron supplements in infancy: results from a randomized controlled trial. American Journal of Clinical Nutrition, 2017, 106, 475-480.	2.2	19
22	Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled. European Respiratory Review, 2017, 26, 170093.	3.0	64
23	Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice. European Respiratory Review, 2017, 26, 170094.	3.0	60
24	Emerging Metabolic Therapies in Pulmonary Arterial Hypertension. Journal of Clinical Medicine, 2017, 6, 43.	1.0	40
25	Management of Anemia. , 2018, , .		2
27	Carbonic anhydrase IX is a critical determinant of pulmonary microvascular endothelial cell pH regulation and angiogenesis during acidosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 315, L41-L51.	1.3	19
28	Pulmonary Arterial Hypertension: Iron Matters. Frontiers in Physiology, 2018, 9, 641.	1.3	20
30	Iron Deficiency as a Therapeutic Target in Cardiovascular Disease. Pharmaceuticals, 2019, 12, 125.	1.7	11
31	Intracellular iron deficiency in pulmonary arterial smooth muscle cells induces pulmonary arterial hypertension in mice. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 13122-13130.	3.3	63
32	BOLA (BolA Family Member 3) Deficiency Controls Endothelial Metabolism and Glycine Homeostasis in Pulmonary Hypertension. Circulation, 2019, 139, 2238-2255.	1.6	54
33	The Search for Disease-Modifying Therapies in Pulmonary Hypertension. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24, 334-354.	1.0	22
34	New and Emerging Therapies for Pulmonary Arterial Hypertension. Annual Review of Medicine, 2019, 70, 45-59.	5.0	68
35	3-Bromopyruvate Attenuates Experimental Pulmonary Hypertension via Inhibition of Glycolysis. American Journal of Hypertension, 2019, 32, 426-432.	1.0	13
36	Iron Homeostasis in the Lungsâ€"A Balance between Health and Disease. Pharmaceuticals, 2019, 12, 5.	1.7	54
37	Trace minerals intake: Risks and benefits for cardiovascular health. Critical Reviews in Food Science and Nutrition, 2019, 59, 1334-1346.	5.4	86
38	Shortâ€term changes in left and right systolic function following ferric carboxymaltose: a substudy of the Myocardialâ€IRON trial. ESC Heart Failure, 2020, 7, 4222-4230.	1.4	21
39	Iron deficiency is a possible risk factor causing right heart failure in Tibetan children living in high altitude area. Medicine (United States), 2020, 99, e21133.	0.4	3

#	Article	IF	Citations
40	Investigational pharmacotherapy and immunotherapy of pulmonary arterial hypertension: An update. Biomedicine and Pharmacotherapy, 2020, 129, 110355.	2.5	12
41	Irp2 regulates insulin production through iron-mediated Cdkal1-catalyzed tRNA modification. Nature Communications, 2020, 11, 296.	5.8	48
42	Impact of Nutrition on Pulmonary Arterial Hypertension. Nutrients, 2020, 12, 169.	1.7	28
43	Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension. European Respiratory Journal, 2020, 55, 1901486.	3.1	26
44	Intravenous iron therapy and the cardiovascular system: risks and benefits. CKJ: Clinical Kidney Journal, 2021, 14, 1067-1076.	1.4	12
45	Single Mutation in the NFU1 Gene Metabolically Reprograms Pulmonary Artery Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 734-754.	1.1	9
46	Iron deficiency in pulmonary arterial hypertension: prevalence and potential usefulness of oral supplementation. Acta Cardiologica, 2021, 76, 162-167.	0.3	8
47	Iron deficiency impacts prognosis but less exercise capacity in heart failure with preserved ejection fraction. ESC Heart Failure, 2021, 8, 1304-1313.	1.4	19
48	Crosstalk between Iron and Arteriosclerosis. Journal of Atherosclerosis and Thrombosis, 2022, 29, 308-314.	0.9	7
49	Iron Deficiency in Pulmonary Arterial Hypertension: A Deep Dive into the Mechanisms. Cells, 2021, 10, 477.	1.8	16
50	Influence of iron manipulation on hypoxic pulmonary vasoconstriction and pulmonary reactivity during ascent and acclimatization to 5050Âm. Journal of Physiology, 2021, 599, 1685-1708.	1.3	17
51	Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders. International Journal of Environmental Research and Public Health, 2021, 18, 1692.	1.2	43
52	Vitamin D improves pulmonary function in a rat model for congenital diaphragmatic hernia. Archives of Biochemistry and Biophysics, 2021, 700, 108769.	1.4	3
53	Predictor factors of pulmonary hypertension in children with left-to-right shunting in acyanotic congenital heart disease. Paediatrica Indonesiana, 2021, 61, 119-24.	0.0	1
54	ERK/Drp1â€dependent mitochondrial fission contributes to HMGB1â€induced autophagy in pulmonary arterial hypertension. Cell Proliferation, 2021, 54, e13048.	2.4	51
55	Supplementation with Iron in Pulmonary Arterial Hypertension. Two Randomized Crossover Trials. Annals of the American Thoracic Society, 2021, 18, 981-988.	1.5	28
56	Iron deficiency in pulmonary arterial hypertension: perspectives. Pulmonary Circulation, 2021, 11, 1-4.	0.8	5
57	Riding the Ferrous Wheel of Iron Supplementation in Pulmonary Arterial Hypertension. Annals of the American Thoracic Society, 2021, 18, 946-948.	1.5	4

#	Article	IF	Citations
58	Ferroptosis: the potential value target in atherosclerosis. Cell Death and Disease, 2021, 12, 782.	2.7	66
59	Intravenous Iron Replacement Improves Exercise Tolerance in COPD: A Single-Blind Randomized Trial. Archivos De Bronconeumologia, 2022, 58, 689-698.	0.4	4
60	Pathobiology of Pulmonary Hypertension. , 2022, , 530-541.		0
61	Mitochondrial metabolism in pulmonary hypertension: beyond mountains there are mountains. Journal of Clinical Investigation, 2018, 128, 3704-3715.	3.9	104
62	Hematological disorders and pulmonary hypertension. World Journal of Cardiology, 2016, 8, 703.	0.5	39
63	Fluid therapy in critically ill patients: perspectives from the right heart. Anaesthesiology Intensive Therapy, 2015, 47, 38-43.	0.4	5
64	Iron Metabolism and Idiopathic Pulmonary Arterial Hypertension: New Insights from Bioinformatic Analysis. BioMed Research International, 2021, 2021, 1-27.	0.9	20
65	Right ventricular function and iron deficiency in acute heart failure. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 406-414.	0.4	8
66	Iron in Cardiovascular Disease: Challenges and Potentials. Frontiers in Cardiovascular Medicine, 2021, 8, 707138.	1.1	27
67	Association of nutritional status and mortality risk in patients with primary pulmonary hypertension. Pulmonary Circulation, 2022, 12, e12018.	0.8	3
68	Cigarette Smoke Particle-Induced Lung Injury and Iron Homeostasis. International Journal of COPD, 2022, Volume 17, 117-140.	0.9	3
69	Iron therapy as a novel treatment of sclerodermaâ€related pulmonary hypertension: A case report and literature review. Respirology Case Reports, 2022, 10, e0904.	0.3	1
70	Mitochondrial Metabolism, Redox, and Calcium Homeostasis in Pulmonary Arterial Hypertension. Biomedicines, 2022, 10, 341.	1.4	13
71	MicroRNAs in Pulmonary Hypertension, from Pathogenesis to Diagnosis and Treatment. Biomolecules, 2022, 12, 496.	1.8	8
72	Ferroptosis in Cardiovascular Diseases: Current Status, Challenges, and Future Perspectives. Biomolecules, 2022, 12, 390.	1.8	17
73	Shortâ€Term Changes in Left and Right Ventricular Cardiac Magnetic Resonance Feature Tracking Strain Following Ferric Carboxymaltose in Patients With Heart Failure: A Substudy of the Myocardialâ€IRON Trial. Journal of the American Heart Association, 2022, 11, e022214.	1.6	5
74	Dan-Shen-Yin Granules Prevent Hypoxia-Induced Pulmonary Hypertension via STAT3/HIF-1Î±/VEGF and FAK/AKT Signaling Pathways. Frontiers in Pharmacology, 2022, 13, 844400.	1.6	9
75	The Latest in Animal Models of Pulmonary Hypertension and Right Ventricular Failure. Circulation Research, 2022, 130, 1466-1486.	2.0	35

#	Article	IF	Citations
76	Multifaceted Roles of Ferroptosis in Lung Diseases. Frontiers in Molecular Biosciences, 0, 9, .	1.6	16
77	Proteomic and Metabolomic Analyses of Right Ventricular Failure due to Pulmonary Arterial Hypertension. Frontiers in Molecular Biosciences, 0, 9, .	1.6	8
78	Induction of GLI1 by miR-27b-3p/FBXW7/KLF5 pathway contributes to pulmonary arterial hypertension. Journal of Molecular and Cellular Cardiology, 2022, 171, 16-29.	0.9	7
79	Can Iron Play a Crucial Role in Maintaining Cardiovascular Health in the 21st Century?. International Journal of Environmental Research and Public Health, 2022, 19, 11990.	1.2	1
80	Iron Deficiency in Heart Failure and Pulmonary Hypertension. Current Treatment Options in Cardiovascular Medicine, 0, , .	0.4	0
81	Bmpr2 mutant mice are an inadequate model for studying iron deficiency in pulmonary hypertension. Pulmonary Circulation, 2022, 12, .	0.8	2
82	Mapping current research and identifying hotspots of ferroptosis in cardiovascular diseases. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	4
83	Iron Deficiency Anemia and COVID-19. Journal of Medical Microbiology and Infectious Diseases, 2022, 10, 157-162.	0.1	0
84	Iron deficiency in pulmonary vascular disease: pathophysiological and clinical implications. European Heart Journal, 2023, 44, 1979-1991.	1.0	9
85	A Panoramic View of Ferroptosis in Cardiovascular Disease. Kidney Diseases (Basel, Switzerland), 2023, 9, 173-186.	1.2	2
86	New Drugs and Therapies in Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 2023, 24, 5850.	1.8	5
89	Molecular regulation and therapeutic implications of cell death in pulmonary hypertension. Cell Death Discovery, 2023, 9, .	2.0	6